Guidant Contak CD CHF Data Mixed But Show Significant Functional Gains
This article was originally published in The Gray Sheet
Executive Summary
Guidant's Contak CD implantable pulse generator significantly improves the functional capacity of patients with congestive heart failure, as evidenced by peak oxygen consumption, although other benefits demonstrated in a 581-patient study did not reach the level of statistical significance, the company says.
You may also be interested in...
Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy
A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.
Guidant Passes On Impulse Buy, Refines Business Grouping For Better Focus
Guidant will pass on an option to acquire exclusive rights to certain Impulse Dynamics experimental heart failure technologies in favor of in-house cardiac resynchronization therapies currently under clinical evaluation in the U.S. and Europe for heart failure.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.